This guide is intended to inform HCPs on how to monitor and manage symptoms associated with CRS and serious neurologic adverse reactions/ICANS, and provide guidance on reporting these serious adverse reactions and any adverse reactions associated with the use of either of these two Kite cellular therapy products.

The Healthcare Professionals Guide has been updated to reflect a post-infusion daily monitoring period of 7 days. Further updates were made, including replacing the requirement to stay within 2 hours of the qualified treatment centre, to stay within proximity of a qualified treatment centre for 4 weeks following infusion.